| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | Mi-er2; KIAA1193 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human MIER2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于MIER2抗体的虚构示例文献(注：内容为模拟生成，仅供参考)：
1. **文献名称**: *MIER2 Antibody Characterization in Epigenetic Regulation Studies*
**作者**: Smith J et al. (2018)
**摘要**: 本研究开发并验证了一种兔源多克隆MIER2抗体，用于染色质免疫沉淀(ChIP)和免疫印迹(WB)。抗体特异性通过siRNA敲低实验确认，证明其在检测人细胞系中MIER2蛋白与染色质结合中的有效性，并揭示MIER2通过组蛋白修饰调控靶基因的机制。
2. **文献名称**: *Role of MIER2 in Breast Cancer Progression: An Immunohistochemical Analysis*
**作者**: Lee H et al. (2020)
**摘要**: 使用商业化小鼠单克隆MIER2抗体(货号ABX-1023)对乳腺癌组织进行免疫组化(IHC)分析。研究发现MIER2在侵袭性肿瘤中表达显著降低，提示其可能作为抑癌因子通过调控ERα信号通路抑制转移。
3. **文献名称**: *Comparative Study of MIER2 Isoforms Using Isoform-Specific Antibodies*
**作者**: Garcia R et al. (2022)
**摘要**: 研究团队设计并验证了两种针对MIER2不同剪接变体(MIER2α和MIER2β)的特异性抗体。通过免疫荧光和流式细胞术，发现两种异构体在细胞核/质分布及细胞周期调控中发挥差异作用。
4. **文献名称**: *MIER2 Antibody Cross-Reactivity Challenges in Murine Models*
**作者**: Wang Y et al. (2021)
**摘要**: 本文报道了常用MIER2抗体在小鼠组织中的非特异性结合问题，通过肽段竞争实验提出优化方案，强调抗体验证对跨物种研究的重要性。
(以上文献信息为模拟生成，实际研究请参考真实数据库如PubMed)
**Background of MIER2 Antibody**
The MIER2 (Mesoderm Induction Early Response 2) protein, encoded by the *MIER2* gene, is a member of the MIER family of transcriptional regulators involved in chromatin remodeling and epigenetic regulation. Initially identified for its role in mesoderm induction during embryonic development, MIER2 interacts with histone deacetylases (HDACs) and other co-repressors to modulate gene expression by altering chromatin structure. It contains conserved domains, including a nuclear localization signal, an acidic transcriptional activation domain, and a chromatin-binding domain, enabling its function in transcriptional repression or activation depending on cellular context.
MIER2 plays a critical role in cell differentiation, proliferation, and apoptosis, with emerging links to cancer biology. Studies suggest it may act as a tumor suppressor or oncogene in a tissue-specific manner, influencing pathways such as Wnt/β-catenin and estrogen receptor signaling. Dysregulation of MIER2 has been implicated in breast cancer, colorectal cancer, and other malignancies.
MIER2 antibodies are essential tools for investigating its expression, localization, and interactions in vitro and in vivo. These antibodies are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to study MIER2's role in development and disease. Researchers also utilize them to explore MIER2's epigenetic regulatory mechanisms, particularly its partnership with HDAC complexes. Validation of antibody specificity remains crucial due to potential cross-reactivity with other MIER family members. Ongoing research continues to unravel MIER2's multifaceted roles, highlighting its therapeutic potential in cancer and developmental disorders.
×
